本帖最后由 老马 于 2012-1-13 21:20 编辑 1 K* m4 G+ l( e" F# [
0 `& y o2 f* }6 g- H爱必妥和阿瓦斯丁的比较
' o1 s+ Z/ A$ n: W: |/ u0 L
) B, O7 ~9 ?6 d% d5 Ohttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/1 h9 w N% C4 W
+ N; `/ ~- R x
4 i2 |* z6 C) g F8 [http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/$ C6 l; Z) j" m$ l
==================================================
+ u2 N( z: j0 C# _( f. F4 zOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL): t8 r. C/ P) y }
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 ^; I/ Z( T+ Q" YResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.' Q1 u0 \, u5 l& b( {6 d% H$ k
|
显身卡
